Latest news in Procedures and Therapies
CMXI’s Aldagen acquisition is no exit; stem cell payoff is still down the road
9 Feb 2012
Cytomedix‘s (OTC:CMXI) Aldagen acquisition signaled the company’s intention to establish a strong presence in regenerative medicine therapies and the deal fills needs for both companies. Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective [...]9 Feb 2012
LINCOLNSHIRE, Ill., Feb. 9, 2012 /PRNewswire/ --Â Board Certified Dermatologist, Dr. Amy Forman Taub, a leading, nationally recognized expert in anti-aging products, treatments and technology, announces ...BioMimetic Therapeutics, Inc. to Introduce Augmatrixâ„¢ Biocomposite Bone Graft Product Line at AAOS
8 Feb 2012
BioMimetic Therapeutics, Inc. today announced it will introduce Augmatrixâ„¢ Biocomposite Bone Graft, a new bone graft substitute product line, to surgeons and distribIn this category: Websites: 0, Number of pages: 0, Last updated: 10 Feb 2012